Medline Campaign Focuses on Ridding Hospital-Acquired Conditions

Medline Industries Inc. (Mundelein, Ill.) this week launched "Prevention Above All," a new campaign targeting the prevention of six hospital-acquired conditions (HACs) and the creation of a $1 million research grant program to support the adoption of evidence-based solutions in health care institutions. Starting Oct. 1, the Centers for Medicare & Medicaid Services (CMS) will pay health care providers a lower-weighted diagnosis-related group for certain HACs when those conditions could have been reasonably prevented by following evidence-based guidelines.

"There are some very innovative and proven solutions available to prevent hospital-acquired conditions," said Medline President Andy Mills. "Our goal with the Prevention Above All campaign is to help health care providers understand the benefits of these solutions and provide the evidence they need to be assured that they offer both clinical and cost-effectiveness."

According to Medline, which manufactures and distributes health care products, there has been much industry discussion on the issue of HACs, but very little of it has centered on the proven solutions available or the challenges of implementation. In addition to providing clarity to the complex issues associated with the CMS policy change, the Prevention Above All campaign also targets a broader issue in health care today--the need to utilize new technologies and better approaches to improve patient care, the company said.

"Implementing innovative solutions is a major challenge for health care providers--many are typically slow adopters when it comes to trying new equipment or different ways of working," Mills said. "Providing targeted interventions that translate research findings into practice will allow healthcare providers to try new technologies with confidence."

Medline said it also aims to stimulate the gathering of solid evidence that supports the adoption of solutions into clinical practice by committing up to $1 million in total costs over several years to fund new grants focused on the HACs CMS has targeted. An independent review panel, whose members represent a breadth of research and practice knowledge, will select grant recipients to be awarded up to $25,000 each for pilot grants or $100,000 each for an empirical study. The first grants will be awarded and funded in 2009 and will cover several areas: pressure ulcers, hand hygiene compliance, retained surgical objects, catheter-associated urinary tract infections, surgical site infections, and other pertinent safety and quality areas. The initial request for proposals is expected to be announced in November.

The program will be chaired by Andrew Kramer, M.D., Head of the Department of Medicine's Health Care Policy and Research Division at the University of Colorado and a frequent advisor to the CMS.

Product Showcase

  • Nextteq® Detector Tube and Pump System product line

    Nextteq® Detector Tube and Pump System product line

    The Nextteq® Detector Tube and Pump System product line from Nextteq® represents well over 500 unique applications utilizing over 300 different kinds of detector tubes as part of a complete sampling analysis system to detect and measure toxic and combustible gases or vapors and materials. Multiple industries are supported and backed by our in-house staff which incorporates a Certified Industrial Hygienist, a Board-Certified Toxicologist, and a Certified Safety Professional to assist you with your technical questions. 3

  • Safety Training

    Safety Training

    Become a Master of Safety Training. Take your safety training from good to great with SafeStart. Improve your personal training skills, discover the training principles that offer maximum impact, and learn the secrets of training for relevance and results. Start delivering top-notch safety training—download the guide today. 3

  • InteliSwab® COVID-19 Rapid Test

    InteliSwab® COVID-19 Rapid Test

    The InteliSwab® COVID-19 Rapid Test from OraSure is a remarkably simple, and easy to use, at-home COVID-19 rapid antigen test. InteliSwab puts the power of rapid results right in your hands. Anytime, anywhere, just swab, swirl and see results in minutes. InteliSwab has been tested against variants of concern and successfully detects Omicron subvariants. By testing frequently in the workplace, you can help prevent disruption and strengthen occupational health. Try InteliSwab today and get your free sample kit here: info.inteliswab.com/2023-paidmedia-ohs-productshowcase-inteliswab-june 3

Featured

Webinars